GSK591
(Synonyms: EPZ015866; GSK3203591) 目录号 : GC14585
A chemical probe for PRMT5
Cas No.:1616391-87-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 4 nM
GSK591 is a PRMT5 inhibitor.
Protein arginine methyltransferase-5 (PRMT5) is found to have a critical role in various cellular processes such as tumorigenesis, and the overexpression of PRMT5 is observed in cell lines and primary patient samples derived from lymphomas, especially mantle cell lymphoma.
In vitro: By further optimization of EPZ015666, an extremely potent in vitro tool analog of EPZ015666, GSK591, was identified. GSK591 was found to maintain excellent selectivity against other PMT enzymes, which was similar to that of EPZ015666. In addition, GSK591 was shown to be an extremely potent compound suitable for in vitro studies with excellent HLM stability [1].
In vivo: In mouse PK studies, GSK591, EPZ015666 and their analogs showed moderate to high plasma clearance and a wide range of oral bioavailability. The volume of distribution values in these studies were from 0.6 to 45 L/kg. Further PK studies demonstrated that at 100 mg/kg in mouse, the unbound plasma concentration was equivalent to or above the IC90 for a period of 12 h, therefore, indicating that the BID dosing regimen of EPZ015666 was able to effectively inhibit PRMT5 in vivo [1].
Clinical trial: Up to now, GSK591 is still in the preclinical development stage.
Reference:
[1] Duncan KW et al. Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. ACS Med Chem Lett. 2015 Dec 2;7(2):162-6.
| Cas No. | 1616391-87-7 | SDF | |
| 别名 | EPZ015866; GSK3203591 | ||
| 化学名 | (S)-2-(cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide | ||
| Canonical SMILES | O=C(C1=CC(NC2CCC2)=NC=C1)NC[C@H](O)CN3CC4=C(C=CC=C4)CC3 | ||
| 分子式 | C22H28N4O2 | 分子量 | 380.48 |
| 溶解度 | ≥ 38mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6283 mL | 13.1413 mL | 26.2826 mL |
| 5 mM | 0.5257 mL | 2.6283 mL | 5.2565 mL |
| 10 mM | 0.2628 mL | 1.3141 mL | 2.6283 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet